Association between Apolipoprotein E genotype and functional outcome in acute ischemic stroke

Aging (Albany NY). 2023 Jan 13;15(1):108-118. doi: 10.18632/aging.204460. Epub 2023 Jan 13.

Abstract

This study aims to determine whether APOE alleles would affect the functional outcome in acute ischemic stroke (AIS) and whether the relationship between inflammation and stroke-related disability varies according to APOE genotypes. We retrospectively collected the demographic and clinical data of AIS patients within one week of symptom-onset through medical records review. The primary outcome was dependence or death, defined as modified Rankin scale (mRS) score of 2-6, which was assessed at 3 months. Among 1929 enrolled patients, the prevalence of APOE ε4 carriers was 17.73% (342/1929). There were 394 AIS patients (394/1929, 20.43%) showed poor function outcome of 90-day mRS (2-6), of whom 147 (147/342, 42.98%) were APOE ε4 carriers and 247 (247/1587, 15.56%) were non-ε4 carriers. There was a significant increased probability of poor functional outcome after AIS among APOE ε4 carriers versus non-ε4 carriers (adjusted-OR 4.62, 95% CI 3.51 to 6.09, P < 0.001). Among ε4 carriers, high neutrophil-to-lymphocyte ratio (NLR) was significantly associated with stroke-related disability (Ptrend = 0.035); however, no significant association was observed among non-ε4 carriers. Our study showed that the APOE ε4 carriers had worse functional outcome after AIS as compared with non-ε4 carriers. APOE genotype may modify the relationship between NLR and 3-month stroke outcome.

Keywords: Apolipoprotein E; functional outcome; neutrophil-to-lymphocyte ratio; stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein E4 / genetics
  • Apolipoproteins E / genetics
  • Genotype
  • Humans
  • Ischemic Stroke*
  • Retrospective Studies
  • Risk Factors
  • Stroke* / epidemiology
  • Stroke* / genetics

Substances

  • Apolipoprotein E4
  • Apolipoproteins E